Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index.
暂无分享,去创建一个
Samin K. Sharma | P. Dehghani | T. Henry | A. Kastrati | G. Dangas | G. Weisz | D. Dudek | S. Mehta | R. Mehran | K. Huber | U. Baber | R. Kornowski | S. Marx | D. Cohen | V. Kunadian | C. Briguori | D. Moliterno | S. Sartori | D. Cao | S. Pocock | D. Angiolillo | V. Džavík | J. Escaned | R. Gil | C. Hamm | U. Kaul | E. Ohman | K. Oldroyd | G. Sardella | R. Shlofmitz | B. Witzenbichler | P. Steg | T. Collier | P. Gurbel | C. Pivato | Zhongjie Zhang | M. Gibson | Mitchell W. Krucoff | D. Cohen | D. Cohen
[1] G. Condorelli,et al. One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients , 2022, Journal of the American Heart Association.
[2] A. Kastrati,et al. Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes , 2021, Clinical Research in Cardiology.
[3] Deepak L. Bhatt,et al. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. , 2021, European heart journal.
[4] P. Serruys,et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials , 2021, BMJ.
[5] Deepak L. Bhatt,et al. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. , 2020, Journal of the American College of Cardiology.
[6] Deepak L. Bhatt,et al. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents , 2020, Circulation.
[7] Y. Jang,et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. , 2020, JAMA.
[8] Samin K. Sharma,et al. Ticagrelor With Aspirin or Alone After Complex PCI: The TWILIGHT-COMPLEX Analysis. , 2020, Journal of the American College of Cardiology.
[9] M. Price,et al. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. , 2020, JACC. Cardiovascular interventions.
[10] P. Serruys,et al. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial , 2020, Clinical Research in Cardiology.
[11] Samin K. Sharma,et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.
[12] N. Cook,et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials , 2018, The Lancet.
[13] E. Grove,et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. , 2018, European heart journal.
[14] G. Vilahur,et al. New insights into the role of adipose tissue in thrombosis , 2017, Cardiovascular research.
[15] D. Tousoulis,et al. The molecular mechanisms of obesity paradox. , 2017, Cardiovascular research.
[16] R. Storey,et al. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . , 2017, International journal of clinical pharmacology and therapeutics.
[17] D. Stanski,et al. Exposure‐Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction , 2017, Journal of clinical pharmacology.
[18] J. Manson,et al. Combined associations of body weight and lifestyle factors with all cause and cause specific mortality in men and women: prospective cohort study , 2016, British Medical Journal.
[19] V. Beral,et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents , 2016, The Lancet.
[20] S. Blair,et al. Obesity and Cardiovascular Disease , 2006 .
[21] B. Lacey,et al. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. , 2016, Circulation research.
[22] S. Schulman,et al. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.
[23] T. Powell-Wiley,et al. Identification of Obesity and Cardiovascular Risk in Ethnically and Racially Diverse Populations: A Scientific Statement From the American Heart Association , 2015, Circulation.
[24] A. Nordström,et al. Risk Factors Assessed in Adolescence and the Later Risk of Stroke in Men: A 33-Year Follow-Up Study , 2014, Cerebrovascular Diseases.
[25] I. Xanthopoulou,et al. Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. , 2014, American heart journal.
[26] S. James,et al. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study. , 2014, Thrombosis research.
[27] Masafumi Ueno,et al. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease , 2013, Thrombosis and Haemostasis.
[28] P. Nichelli,et al. Obesity and the Risk of Intracerebral Hemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy , 2013, Stroke.
[29] R. Koppensteiner,et al. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. , 2013, Translational research : the journal of laboratory and clinical medicine.
[30] Jeroen J. Bax,et al. Third universal definition of myocardial infarction , 2013, Nature Reviews Cardiology.
[31] W. Ruf,et al. Inflammation, obesity, and thrombosis. , 2012, Blood.
[32] D. Foley,et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. , 2012, Journal of the American College of Cardiology.
[33] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[34] D. Foley,et al. The role of weight and enteric coating on aspirin response in cardiovascular patients , 2010, Journal of thrombosis and haemostasis : JTH.
[35] Jonathan E. Dickerson,et al. Supplementary webappendix , 2013 .
[36] H. Yatsuya,et al. Body Mass Index and Risk of Stroke and Myocardial Infarction in a Relatively Lean Population: Meta-Analysis of 16 Japanese Cohorts Using Individual Data , 2010, Circulation. Cardiovascular quality and outcomes.
[37] Dick M. Goedhart,et al. The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). , 2010, The American journal of cardiology.
[38] Jiang He,et al. Body mass index and risk of stroke among Chinese men and women , 2010, Annals of neurology.
[39] P. Barragan,et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. , 2009, The American journal of cardiology.
[40] A. Skene,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[41] C. Lavie,et al. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. , 2009, Journal of the American College of Cardiology.
[42] F. Andreotti,et al. Body fat and cardiovascular risk: understanding the obesity paradox. , 2008, European heart journal.
[43] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[44] S. Ebrahim,et al. Body Mass Index and Ischemic and Hemorrhagic Stroke: A Prospective Study in Korean Men , 2004, Stroke.
[45] C. Macaya,et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? , 2004, The Journal of invasive cardiology.
[46] R. Virmani,et al. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. , 1998, Circulation.
[47] K. Mann,et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.
[48] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.